FoxM1 over-expression was associated with adverse clinico-pathological parameters such as high grade serous carcinomas (p = 0.0221), poorly differentiated tumors (p = 0.0024) and high proliferative index (Ki-67, p = 0.0007) (Table 1). This evidence concerns the gene FOXM1 and serous adenocarcinoma.